Molecular Studies and Clinical Correlations in Human Prostatic Disease
The therapeutics program for advanced prostate cancer is based on the hypothesis that the
factors contributing to and associated with progression change as the disease evolves. To
categorize these changes we now consider the disease as a series of states. 1 The states
represent points where an intervention might be considered to prevent cancer from
developing, to eliminate established disease, or to delay progression. The states also
represent clinically significant milestones that can be used to assess treatment effects.
Observational
Observational Model: Case-Only
Susan Slovin, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
90-040
NCT00578240
April 1990
December 2014
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |